Skip to main content
Premium Trial:

Request an Annual Quote

MDS Expands with New Facilities in US, Denmark

NEW YORK, March 20 – Toronto-based MDS Proteomics said Tuesday it has opened a new facility in Odense, Denmark and is in the process of building new facilities in Boston and Charlottesville, NC.

The facility in Odense employs more than 60 scientists and has a number of customized mass spectrometers as well as one of the largest Linux clusters, with 101 computers that each have 2 x 1 Ghz CPU and 2 GB ram, the company said. 

"MDS Proteomics recognizes that by increasing our geographic footprint, we can continue to attract the most talented scientists located in major biotechnology centers worldwide,” Frank Gleeson, MDS Proteomics’ CEO, said in a statement.

The company, a subsidiary of MDS, is also expanding its Toronto facility, where it analyzes protein interaction pathways and produces data for its proprietary BIND database, which is used to select and validate targets for its customers.

Earlier this year IBM invested $10 million in MDS Proteomics as part of a strategic collaboration that also included an agreement to jointly establish BIND, a publicly available web-based protein database based in Toronto.

At the Boston facility, scientists will focus on high throughput screening, structural biology and drug design, medicinal chemistry, and protein identification. And, the Charlottesville complex will specialize in the analysis of complex mixtures of proteins to identify novel membrane bound receptor proteins as targets for therapeutic drugs. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.